1-5 of 5
Elizabeth A. Coker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

Elizabeth A. Coker, Adam Stewart, Bugra Ozer, Anna Minchom, Lisa Pickard, Ruth Ruddle, Suzanne Carreira, Sanjay Popat, Mary O'Brien, Florence Raynaud, Johann de Bono, Bissan Al-Lazikani, Udai Banerji
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 1020–1029.
https://doi.org/10.1158/1535-7163.MCT-21-0442
Published: 01 June 2022
View article titled, Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
Open the PDF for Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes in another window
Includes: Supplementary data
Journal Articles

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

Vikki Flemington, Emma J. Davies, David Robinson, Linda C. Sandin, Oona Delpuech, Pei Zhang, Lyndsey Hanson, Paul Farrington, Sigourney Bell, Katarzyna Falenta, Francis D. Gibbons, Nicola Lindsay, Aaron Smith, Joanne Wilson, Karen Roberts, Michael Tonge, Philip Hopcroft, Sophie E. Willis, Martine P. Roudier, Claire Rooney, Elizabeth A. Coker, Patricia Jaaks, Mathew J. Garnett, Stephen E. Fawell, Clifford D. Jones, Richard A. Ward, Iain Simpson, Sabina C. Cosulich, J. Elizabeth Pease, Paul D. Smith
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (2): 238–249.
https://doi.org/10.1158/1535-7163.MCT-20-0002
Published: 05 February 2021
View article titled, AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <em>KRAS</em>-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Open the PDF for AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <em>KRAS</em>-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib in another window
Includes: Supplementary data
Journal Articles

Abstract C007: A high-throughput screen to identify effective and translationally-relevant drug combinations for breast, colorectal, and pancreatic cancers

Elizabeth A Coker, Patricia Jaaks, Daniel J Vis, Nanne Aben, Syd Barthorpe, Dieudonne van der Meer, Howard Lightfoot, Lodewyk Wessels, Mathew Garnett, GDSC Screening Team
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C007.
https://doi.org/10.1158/1535-7163.TARG-19-C007
Published: 01 December 2019
View article titled, Abstract C007: A high-throughput screen to identify effective and translationally-relevant drug combinations for breast, colorectal, and pancreatic cancers
Journal Articles

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

Adam Stewart, Elizabeth A. Coker, Sebastian Pölsterl, Alexandros Georgiou, Anna R. Minchom, Suzanne Carreira, David Cunningham, Mary ER. O'Brien, Florence I. Raynaud, Johann S. de Bono, Bissan Al-Lazikani, Udai Banerji
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (8): 1396–1404.
https://doi.org/10.1158/1535-7163.MCT-18-0727
Published: 01 August 2019
View article titled, Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in <em>KRAS</em>-Mutant Cancers
Open the PDF for Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in <em>KRAS</em>-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract B096: canSAR, a cancer research and drug discovery knowledgebase

Elizabeth A. Coker, Patrizio Di Micco, Joesph E. Tym, Costas Mitsopoulos, Angeliki Komianou, Albert A. Antolin, Bissan Al-Lazikani
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B096.
https://doi.org/10.1158/1535-7163.TARG-17-B096
Published: 01 January 2018
View article titled, Abstract B096: canSAR, a cancer research and drug discovery knowledgebase